company background image
300233 logo

Shandong Jincheng Pharmaceutical Group SZSE:300233 Stock Report

Last Price

CN¥15.20

Market Cap

CN¥5.8b

7D

-5.8%

1Y

-23.3%

Updated

21 Apr, 2024

Data

Company Financials

Shandong Jincheng Pharmaceutical Group Co., Ltd

SZSE:300233 Stock Report

Market Cap: CN¥5.8b

300233 Stock Overview

Shandong Jincheng Pharmaceutical Group Co., Ltd, together with its subsidiaries, researches and develops, produces, markets, and sells Cephalosporin intermediates in China and internationally.

300233 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance1/6
Financial Health5/6
Dividends4/6

Shandong Jincheng Pharmaceutical Group Co., Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shandong Jincheng Pharmaceutical Group
Historical stock prices
Current Share PriceCN¥15.20
52 Week HighCN¥22.09
52 Week LowCN¥10.83
Beta0.35
1 Month Change-7.03%
3 Month Change11.76%
1 Year Change-23.31%
3 Year Change-35.32%
5 Year Change-19.23%
Change since IPO49.24%

Recent News & Updates

Shandong Jincheng Pharmaceutical Group's (SZSE:300233) Problems Go Beyond Weak Profit

Apr 04
Shandong Jincheng Pharmaceutical Group's (SZSE:300233) Problems Go Beyond Weak Profit

Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) Shares Climb 29% But Its Business Is Yet to Catch Up

Mar 04
Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) Shares Climb 29% But Its Business Is Yet to Catch Up

Shandong Jincheng Pharmaceutical Group (SZSE:300233) Seems To Use Debt Quite Sensibly

Mar 02
Shandong Jincheng Pharmaceutical Group (SZSE:300233) Seems To Use Debt Quite Sensibly

Recent updates

Shandong Jincheng Pharmaceutical Group's (SZSE:300233) Problems Go Beyond Weak Profit

Apr 04
Shandong Jincheng Pharmaceutical Group's (SZSE:300233) Problems Go Beyond Weak Profit

Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) Shares Climb 29% But Its Business Is Yet to Catch Up

Mar 04
Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) Shares Climb 29% But Its Business Is Yet to Catch Up

Shandong Jincheng Pharmaceutical Group (SZSE:300233) Seems To Use Debt Quite Sensibly

Mar 02
Shandong Jincheng Pharmaceutical Group (SZSE:300233) Seems To Use Debt Quite Sensibly

Shareholder Returns

300233CN PharmaceuticalsCN Market
7D-5.8%-1.1%-0.4%
1Y-23.3%-15.9%-16.2%

Return vs Industry: 300233 underperformed the CN Pharmaceuticals industry which returned -15.9% over the past year.

Return vs Market: 300233 underperformed the CN Market which returned -16.2% over the past year.

Price Volatility

Is 300233's price volatile compared to industry and market?
300233 volatility
300233 Average Weekly Movement7.4%
Pharmaceuticals Industry Average Movement7.9%
Market Average Movement8.9%
10% most volatile stocks in CN Market12.7%
10% least volatile stocks in CN Market5.4%

Stable Share Price: 300233 has not had significant price volatility in the past 3 months.

Volatility Over Time: 300233's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20043,806Jiaquan Liwww.jinchengpharm.com

Shandong Jincheng Pharmaceutical Group Co., Ltd, together with its subsidiaries, researches and develops, produces, markets, and sells Cephalosporin intermediates in China and internationally. The company offers active pharmaceutical ingredients, biopharmaceuticals, medical intermediates, fine chemicals, finished dosages, and pharmaceutical products. It also provides animal nutrition and health care, as well as CMO and CDMO services.

Shandong Jincheng Pharmaceutical Group Co., Ltd Fundamentals Summary

How do Shandong Jincheng Pharmaceutical Group's earnings and revenue compare to its market cap?
300233 fundamental statistics
Market capCN¥5.83b
Earnings (TTM)CN¥174.71m
Revenue (TTM)CN¥3.54b

33.4x

P/E Ratio

1.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300233 income statement (TTM)
RevenueCN¥3.54b
Cost of RevenueCN¥2.07b
Gross ProfitCN¥1.46b
Other ExpensesCN¥1.29b
EarningsCN¥174.71m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 25, 2024

Earnings per share (EPS)0.46
Gross Margin41.40%
Net Profit Margin4.94%
Debt/Equity Ratio14.5%

How did 300233 perform over the long term?

See historical performance and comparison

Dividends

1.3%

Current Dividend Yield

44%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.